Sunshine Act
11.8.2011 Fair-Market Value
Physician’s Conflict of Interest in Spotlight Again after BMJ Study Published
By Ryan McGuire,Senior Research Analyst
A study published in the British Medical Journal has received a lot of attention lately. It highlighted the prevalence of financial conflicts of interest (COI) for researchers sitting on 14 specific guideline-setting...
7.27.2011 Clinical Development
Sunshine Act Presents Uncertainty for Clinical Development
The sunshine provision of the landmark U.S. healthcare law passed in 2010 requires that drug and device manufacturers report all gifts and payments exceeding $10 in value. While the law seems clear for consulting fees, it becomes quite murky when discussing clinical...
7.22.2011 Medical Affairs
Hard Limits on Thought Leader Compensation Employed Less Often by Pharma
As compliance and medical affairs teams prepare for the Sunshine Act, they are relying less on exact compensation limits for key opinion leaders. “KOL Fair-Market Value and Aggregate Spend: Documentation, Tracking and the Sunshine Act” found that only 35...
7.11.2011 Fair-Market Value
What Pharma and Biotech Companies Are Currently Paying European Key Opinion Leaders
Cutting Edge Information’s new research on European fair-market value benchmarks found that drug manufacturers spend between €153 and €283 for a typical key opinion leader (KOL) engagement. Payments vary by company size; biotechnology companies pay European...
6.14.2011 Fair-Market Value
Key Opinion Leader Payments Drop by 50%
Average physician fee schedules for hourly payments to KOLs have fallen each year since 2006, finds Cutting Edge Information
Drug and device manufacturers have responded to criticism over physician payments by decreasing their average level of compensation by...
6.1.2011 Fair-Market Value
Sunshine Act Impacts Drug Companies’ Promotional Activities
Although the Sunshine Act requires disclosures for grants and other funding of medical research, the majority of payment categories are focused on promotional engagements. A new report from Cutting Edge Information finds that drug manufacturers are feeling the...
4.12.2011 KOL Management
Drug Companies Embrace Proactive Approach to Transparency
Cutting Edge Information Declares Series of New Disclosure Laws Not Yet Over
The wave of pharmaceutical transparency laws has not yet crested, according to research from Cutting Edge Information, and drug companies are responding with steps to reveal their compensation...
2.8.2011 KOL Management
Transparency Could Hamper Thought Leader Relationships
As drug companies face requirements to report all spending on physician-related activity, relationships between thought leaders and drug manufacturers are feeling the strain. Aside from individual state laws requiring companies to report payments to physicians,...
1.16.2011 KOL Management
Sunshine Act is Now Law: Will KOL Relationships be Impacted?
The Sunshine Act, originally drafted in 2007, has been made law as part of the Patient Protection and Affordable Care Act. What passed was really a revised version of the original, of course, but the Sunshine Act is now the law of the land, and that will impact...







